{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-25-031574","form_type":"8-K","ticker":"MBRX","cik":"0001659617","company_name":"Moleculin Biotech, Inc.","filed_at":"2025-10-23T23:59:59+00:00","discovered_at":"2026-05-14T18:02:40.065758+00:00","generated_at":"2026-05-17T02:31:09.421241+00:00","sec_items":["7.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Moleculin announces investigator-initiated Phase 1B/2 study of Annamycin for pancreatic cancer","bullets":["Phase 1B/2 single-arm study of Annamycin for third-line advanced pancreatic cancer; investigator-initiated by Atlantic Health.","Moleculin supplies Annamycin and maintains IND; Dr. Angela Alistar (Atlantic Health) is principal investigator.","Estimated additional cost to Moleculin ~$1M from 2026 to 2030 for drug supply and testing.","Preclinical data shows Annamycin targets topoisomerase II, correlated with poor survival in pancreatic cancer.","Annamycin (naxtarubicin) has Fast Track and Orphan Drug status for AML; Orphan Drug for STS lung mets."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-25-031574","json":"https://secwatch.observer/filing/0001437749-25-031574.json","markdown":"https://secwatch.observer/filing/0001437749-25-031574.md","text":"https://secwatch.observer/filing/0001437749-25-031574.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925031574/0001437749-25-031574-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1659617/000143774925031574/mbrx20251020_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-17T02:31:09.421241+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}